Biontech to acquire kite's neoantigen tcr cell therapy r&d platform and manufacturing facility in gaithersburg, md

Mainz, germany & santa monica, calif.--(business wire)--biontech se (nasdaq: bntx, “biontech”) and kite, a gilead company (nasdaq: gild, “kite”) today announced the two companies have entered into a purchase agreement for biontech to acquire kite's solid tumor neoantigen t cell receptor (tcr) r&d platform and clinical manufacturing facility in gaithersburg, md. the acquired gaithersburg facility will provide production capacity to support clinical trials in the united states and will comple
BNTX Ratings Summary
BNTX Quant Ranking